Posters

      iTRAQ approach to investigate the impact of cigarette smoke, smoking cessation and switching to a prototypic modified risk tobacco product on the lung proteome of C57BL/6 mice

      Schneider, T.; Dijon, S.; Elamin, A.; Phillips, B.; Veljkovic, E.; Titz, B.; Martin, F.; Ivanov, N. V.; Hoeng, J.; Peitsch, M. C.

      Conference date
      Oct 5, 2014
      Conference name
      13th Annual World Congress of the Human Proteome Organization (HUPO)
      Link to more information
      Link to more information
      Topic
      Summary

      Reliable system-wide measurements are key to a meaningful systems-toxicology approach by which impact of toxicants in cells are evaluated (Hoeng et al., 2012). While still being challenging to setup, liquid-chromatography mass-spectrometry (LC-MS) based quantitative proteomics may lead to a further understanding of systems response and complement the widely used transcriptomics data. In the context of a life-long animal study aiming at characterizing the impact of cigarette smoke in mouse lung and the effect of cessation and switching to a prototypic Modified Risk Tobacco Product (pMRTP), we established an isobaric tags for absolute and relative quantification (iTRAQ®)-based pipeline aiming at capturing a wide variety of proteins. The arms of  this animal study involving C57/Bl6 mice were exposure to: (i) fresh-air only, (ii) conventional cigarette smoke (CS) from 3R4F cigarettes (from University of Kentucky),  (iii) CS and switch to a pMRTP,  (iv) CS and switch to fresh air (cessation) and (v) pMRTP only. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.